• SEC Filings

On August 3, 2017, IRIDEX Corporation issued a press release discussing revenues for its second fiscal quarter of 2017, which ended July 1, 2017.The press release is attached hereto as Exhibit99.1 and is incorporated herein by reference.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

IRIDEX CORP Exhibit
EX-99.1 2 irix-ex991_6.htm EX-99.1 irix-ex991_6.htm Exhibit 99.1       IRIDEX Announces 2017 Second Quarter,…
To view the full exhibit click here

About IRIDEX CORPORATION (NASDAQ:IRIX)

IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.